Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
Sign Up to like & getrecommendations! Published in 2022 at "BMC Cancer"
DOI: 10.1186/s12885-021-09115-6
Abstract: Background Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction (GEJ) cancer could be demonstrated in predominantly Asian cohorts, whereas data in Western patients outside of clinical trials are vastly missing.… read more here.
Keywords: cancer; gej cancer; gastric gej; real world ... See more keywords
CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps4131
Abstract: TPS4131Background: Expression of the PD-1 ligands PD-L1 and PD-L2 has been reported in ≈ 40% of pts with E/GEJ cancer and is associated with a poor prognosis. In a phase 3 trial, the PD-1 inhibitor… read more here.
Keywords: gej cancer; phase; nivo; cancer ... See more keywords
A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.383
Abstract: 383Background: Nivo is the first immune checkpoint inhibitor (ICI) to show efficacy and tolerability in G/GEJ cancer patients refractory to or intolerant of standard chemotherapy. Although Nivo has... read more here.
Keywords: gej cancer; phase iii; iii study; study nivolumab ... See more keywords
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24054877
Abstract: Resectable gastric or gastroesophageal (G/GEJ) cancer is a heterogeneous disease with no defined molecularly based treatment strategy. Unfortunately, nearly half of patients experience disease recurrence despite standard treatments (neoadjuvant and/or adjuvant chemotherapy/chemoradiotherapy and surgery). In… read more here.
Keywords: gej; gej cancer; times changing; growth factor ... See more keywords
Safety and efficacy of the FLOT regimen in the Polish population - an analysis of the prospective trial.
Sign Up to like & getrecommendations! Published in 2022 at "Neoplasma"
DOI: 10.4149/neo_2022_220720n734
Abstract: As gastric cancer is associated with poor prognosis, the preferred management of locally advanced gastric cancer (GC) and gastroesophageal junction (GEJ) cancer in European patients is perioperative chemotherapy using the FLOT regimen. Previously published data… read more here.
Keywords: safety; gej cancer; efficacy; flot regimen ... See more keywords